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Abstract
Sarcomas are mesenchymal cancers with poor prognosis, representing about 20% of all solid malignancies in children,
adolescents, and young adults. Radio- and chemoresistance are common features of sarcomas warranting the search
for novel prognostic and predictive markers. GARP/LRRC32 is a TGF-β-activating protein that promotes immune
escape and dissemination in various cancers. However, if GARP affects the tumorigenicity and treatment resistance of
sarcomas is not known. We show that GARP is expressed by human osteo-, chondro-, and undifferentiated
pleomorphic sarcomas and is associated with a significantly worse clinical prognosis. Silencing of GARP in bone
sarcoma cell lines blocked their proliferation and induced apoptosis. In contrast, overexpression of GARP promoted
their growth in vitro and in vivo and increased their resistance to DNA damage and cell death induced by etoposide,
doxorubicin, and irradiation. Our data suggest that GARP could serve as a marker with therapeutic, prognostic, and
predictive value in sarcoma. We propose that targeting GARP in bone sarcomas could reduce tumour burden while
simultaneously improving the efficacy of chemo- and radiotherapy.
Introduction
Primary bone sarcomas, which mainly includes osteo-
sarcoma, chondrosarcoma, and Ewing sarcoma, are a
group of rare tumours of mesenchymal or ectodermal
origin that constitutes <0.2% of all malignancies in
adults1. However, high grade osteo- and Ewing sarcomas
mostly affect children and young adults (<20 years) where
they account for about 3.5% and 2%, respectively, of all
solid cancers2. Although advances in surgery and multi-
agent chemotherapy have markedly improved prognosis
and overall survival of bone sarcoma, the 5-year survival
rate remains at 60–70% for patients with localised disease,
and as low as 20–30% for patients with metastatic dis-
ease3–5. The poor prognosis of bone sarcomas is in part
linked to resistance to conventional chemotherapy (CT)
and radiation therapy (RT)6–8. This makes cancers in the
bone and cartilage the third most important cause of
cancer-related death in children and adolescents in the
United States9. Thus, there is an urgent need for new
therapies, biomarkers (diagnostic, prognostic, or ther-
apeutic), and a greater understanding of the mechanisms
behind the chemo- and radioresistance of bone sarcomas.
Transforming growth factor (TGF)-β is a pleiotropic
cytokine that regulates proliferation, angiogenesis, carcino-
genesis, and immune responses10. TGF-β is produced as an
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inactive complex consisting of the mature TGF-β homo-
dimer bound to the latency-associated peptide (LAP). A
conformational change in the LAP induced by integrins,
proteases, or reactive oxygen species releases TGF-β11,
which then can bind its receptors and induce signalling via
canonical (mothers against decapentaplegic homolog;
SMADs) and non-canonical pathways12. While TGF-β
initially acts as a tumour suppressor, at later stages of car-
cinogenesis it promotes tumour growth and metastasis via
induction of epithelial-to-mesenchymal transition (EMT),
inhibition of the anti-tumour immune response, and the
recruitment/induction of cancer-associated fibroblasts into
the tumour microenvironment13. Furthermore, recent data
suggest that TGF-β also can play a role in the chemo- and
radioresistance of tumours14.
Glycoprotein A repetitions predominant (GARP)/leu-
cine rich repeat containing 32 (LRRC32)15 binds and
activates latent TGF-β1 on the surface of regulatory
T cells (Tregs) and B cells, promoting their immuno-
suppressive function and isotype switching, respec-
tively16–18. GARP-overexpression in colorectal and lung
cancer is associated with a worse prognosis due to a TGF-
β-dependent pro-metastatic effect and to the induction of
an immunosuppressive tumour microenvironment19–21.
Mesenchymal stem cells (MSCs) are non-haematopoietic,
multipotent cells that can give rise to bone, cartilage, and
adipocytes22. MSCs are a key component of the bone mar-
row (BM) where they regulate haematopoiesis23 and parti-
cipate in bone homoeostasis13. Abundant evidence suggests
that oncogenic events during the differentiation of MSCs can
give rise to sarcomas24,25. We recently found that adipose
tissue-derived MSCs (ASCs) express GARP in vitro, which
binds latent TGF-β1 to their surface26,27. However, whether
GARP is expressed on bone sarcoma cells and if GARP can
promote their tumorigenicity and/or chemo/radioresistance
are unknown.
In this work, we show that GARP is expressed on several
established and freshly isolated patient-derived bone sarcoma
primary cell lines. Silencing of GARP inhibited their pro-
liferation, whereas overexpression of GARP increased their
proliferation in vitro and in vivo, via a TGF-β-dependent
mechanism. GARP-overexpressing bone sarcoma cells were
more resistant to etoposide-, doxorubicin-, and radiation-
induced cell death in vitro. Importantly, GARP was found to
be overexpressed in human osteo-, chondro-, and pleo-
morphic sarcomas and was associated with a significantly
worse clinical prognosis. Our data suggest that GARP might
serve as a target and/or biomarker with therapeutic, prog-
nostic, and predictive value for bone sarcoma tumours.
Materials and methods
Cell cultures
The osteosarcoma cell lines G292, T1–73, and SAOS-2
were obtained from the American Type Culture
Collection (ATCC). The OST-3 and OST-4 primary cell
lines were generated from tumour samples surgically
resected at the Hospital Universitario Central de Asturias
(Oviedo, Spain). OST-3 derives from a conventional
osteoblastic osteosarcoma resected from a 10-year-old
female patient and OST-4 corresponds to a dediffer-
entiated osteosarcoma from a 69-year-old female patient.
The chondrosarcoma cell line T-CDS17 was previously
described28. All cell lines were cultured in Advanced
DMEM (Invitrogen) with 10% FBS (Biowest), 1% Gluta-
max (Gibco, Thermo Fisher Scientific), and 100 U/ml
penicillin/streptomycin (Gibco, Thermo Fisher Scientific)
at 37 °C, 5% CO2. The Ewing’s sarcoma cell line RD-ES
was cultured in RPMI-1640 (Gibco, Thermo Fisher Sci-
entific) supplemented with 10% FBS and 100 U/ml peni-
cillin/streptomycin. All cell lines were routinely tested for
mycoplasma contamination. The analysis of GARP
expression by RT-PCR and flow cytometry, the produc-
tion of lentiviral vectors (LVs) and transduction of cells,
the analysis of cell proliferation in vitro, cell viability in
response to etoposide and doxorubicin, the measurement
of double-strand DNA breaks (DSBs), and the production
of active TGF-β are described in detail in the Supple-
mentary materials and methods.
Analysis of tumour growth in vivo
Female NOD scid gamma (NSG) mice (8–12 weeks)
were obtained from the Centro de Investigaciones Bio-
médicas (CIBM, Granada, Spain). All experiments were
performed according to the Institutional Guidelines for
the Care and Use of Laboratory Animals in Research, with
the approval of the Ethics Committee in Animal Research
at the University of Granada (Granada, Spain). A pilot
experiment was performed using NT G292 cells in order
to determine the optimal cell number needed to obtain a
controlled and reproducible tumour growth over time,
and thus sample size according to the replacement,
replacement and reduction framework for ethical animal
use. Mice were allocated into four groups using complete
randomisation. Non-transduced (NT), LV-CTRL (cells
transduced with a LV encoding a non-targeting shRNA),
GARPKO2 (cells transduced with an LV encoding a
GARP-specific shRNA), and GARP++ (cells transduced
with an LV encoding a GARP cDNA) G292 (4 × 106) cells,
in PBS, were injected subcutaneously and tumour growth
and body weight were measured every 6–7 days in a non-
blinded fashion. Tumour volume was calculated using the
formula: (π/6) × (a2 × b) where a and b represent the
values for the smaller and the larger tumour diameter,
respectively. After 2–3 months (or when the tumour
volume reached 1800 mm3), mice were sacrificed,
tumours were removed and tumour volumes and weights
were measured. Pre-established criteria for exclusion
included a 15% loss of total body weight, breathing
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difficulties, persistent lordosis, continuous salivation, or
convulsions. Immunohistochemistry was performed on
paraffin-embedded tissue sections using monoclonal
antibodies against human Ki67 (MIB-1, DAKO/Agilent,
Santa Clara, CA, Agilent, Cat#: F726801) and
phosphorylated-SMAD3 (phosphoS423+ S425, EP823Y,
Abcam, Cambridge, UK, Abcam, Cat#: 1880-1) as
described in Supplementary materials and methods.
Clonogenic assay
Non-transduced (NT) and GARP-overexpressing
(GARP++) SAOS-2 and RD-ES cells were added to 6-
well plates at various densities: 2000, 4000, 8000, and
160,000 cells/well (NT) and 1000, 2000, 4000, 8000 cells/
well (GARP++). Cells were exposed to γ-radiation using a
L. Shepherd & associates MARK-I model 30 Caesium-137
irradiator at the Experimental Radiology Unit, University
of Granada (Spain), with single fractions of 0, 2, 4, and
8 Gy, using a dose rate of 1.66 Gymin-1. In some experi-
ments, SB431542 (10 µM) was added 24 h before irradia-
tion. Cells were maintained in culture until the
appearance of countable colonies (7–9 days following
irradiation). Cells were fixed and stained with crystal
violet and colonies counted (colonies with >50 cells/col-
ony were scored for survival). The surviving fraction was
calculated as previously described29.
Patients, tissue specimens, and IHC
Paraffin-embedded tissues from 89 patients with sar-
coma who underwent resection of their tumours at the
Hospital Universitario Central de Asturias (HUCA) were
studied. Samples and clinical data from donors included
in this study were provided by the Principado de Asturias
BioBank (PT17/0015/0023) integrated in the Spanish
National Biobanks Network and they were processed
following standard operating procedures with the appro-
priate approval of the Ethical and Scientific Committees.
All samples from human origin were obtained upon
signed informed consent. Sixty percent of the cases were
men; mean age at diagnosis was 49 years (range 2–89
years). Twenty eight (31%) patients had a history of
tobacco consumption (15 current and 13 former smo-
kers). Tumour grade was evaluated in H&E-stained pre-
parations using the French Federation of Comprehensive
Cancer Centres grading system30. Clinicopathological
features of the patients are included in Table S1. Con-
struction of the tissue microarray (TMA) and the staining
of the TMA for GARP and subsequent scoring are
described in Supplementary materials and methods.
Statistical analysis
For the in vitro experiments and the tumour growth
experiment in vivo, the statistical analysis was performed
using the GraphPad Prism software (GraphPad Software,
Inc, La Jolla, CA). All data are represented as mean (SD) of
at least three independent experiments unless otherwise
stated in the figure legend. Data sets were tested for nor-
mality using the Shapiro-Wilk test. A Student’s t-test was
used for pairwise comparisons while multiple comparisons
of the data were performed using the one-way ANOVA,
followed by the Bonferroni post test. According to both
tests there were no significant differences in variance
between the compared groups. The statistical analysis of the
clinical data was carried out using the software package
SPSS 24 (SPSS, IBM corp.). The experimental results dis-
tributed among the different clinical groups of tumours
were tested for significance employing the χ2-test (with
Yates’ correction, when appropriate). For statistical pur-
poses continuous variables (age, tumour size) were dichot-
omised, taking the median value as a cut-off point. Survival
curves were calculated using the Kaplan-Meier product
limit estimate. Differences between survival times were
analysed by the log-rank method and the hazard ratio was
calculated by univariate Cox regression analysis. Multi-
variate Cox proportional hazards models (forward Wald
method) were used to examine the relative impact of those
variables statistically significant in univariate analysis. All
tests were two-sided and P values < 0.05 were considered
statistically significant.
Results
GARP is expressed on several bone sarcoma cancer cell
lines and its silencing blocks their proliferation
An analysis of the Cancer Cell Line Encyclopedia
(CCLE) database revealed that elevated GARP mRNA
expression could be found in several sarcoma subtypes,
including giant cell tumours, osteosarcomas, and chon-
drosarcomas, with relatively lower levels in carcinoma and
glioma cell lines (Fig. 1A). These data were corroborated
by a GARP qPCR on human bone marrow-derived (BM)-
MSCs, osteosarcoma cells (G292, T1–73, and SAOS-2),
an Ewing sarcoma cell line (RD-ES), two glioblastoma cell
lines (U87, U251), and two carcinoma cell lines (HT-29,
MCF-7) (Fig. 1B) and by flow cytometry (Figs. 1C and
S1A). Silencing of GARP in BM-MSCs, G292, T1–73, and
SAOS-2 cells (Figs. S1B, S1C, and S2), using LVs encoding
for two distinct GARP-specific shRNAs (GARPKO1 and
GARPKO2), decreased their proliferative capacity com-
pared to non-transduced (NT) and control transduced
(LV-CTRL) cells (Fig. 1D, E) and increased cell death by
apoptosis (Fig. 1F).
GARP promotes the proliferation of bone sarcoma cell
lines through activation of TGF-β
We next analysed the effect of GARP-overexpression on
the proliferation of various bone sarcoma cells. To this
end, we overexpressed GARP (GARP++) in G292, SAOS-
2, and RD-ES cells using a LV encoding a
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codon-optimised human GARP cDNA under the control
of the CMV promoter (Fig. 2A). Parallelly, control cells
were transduced with LV encoding for the enhanced
green fluorescent protein (EGFP++). GARP++ cells
exhibited an increased proliferative capacity compared to
NT and EGFP++ cells (Fig. 2B, C). We next assessed
whether GARP-overexpression could increase the acti-
vation of TGF-β. No active TGF-β was detected in non-
acidified supernatants from NT and GARP++ sarcoma
cells by conventional ELISA (data not shown). However,
using a TGF-β activity reporter cell line, we found that
GARP++ cells produced significantly higher levels of
active TGF-β compared to NT cells (Figs. 2D and S3).
Blocking TGF-β signalling with SB431542 or neutralising
TGF-β using an anti-TGF-β1/2/3 antibody significantly
reduced the proliferation of the GARP++ cells (Fig. 2E).
GARP increases the growth of G292 tumours in vivo
In order to analyse whether the expression levels of
GARP are also important for tumour growth in vivo, we
Fig. 1 GARP is expressed on several bone sarcoma cancer cell lines and its silencing blocks their proliferation. A GARP mRNA expression
data from various cancer cell lines retrieved from the CCLE data base. The numbers in parentheses indicate the number of cell lines analysed/cancer
type. RMA log2 mRNA expression values are shown as box plots and sorted by the median in descending order from left to right. Outliers are plotted
as filled circles. B GARP mRNA expression in primary BM-MSCs and various cancer cell lines. Data are shown as mean (SD), relative to the GARP
expression in BM-MSCs. C Summary of GARP expression (% in relation to isotype control) on primary BM-MSCs and selected bone sarcoma cell lines.
Data are shown as mean (SD) of three individual stainings. D Silencing of GARP in BM-MSCs and the osteosarcoma cell lines G292, T1–73, and SAOS-2
inhibits their proliferation. Proliferation (cell index) of non-transduced (NT), LV-CTRL, GARPKO1, and GARPKO2 cells was measured in real-time during
7 days. Data are shown as mean (SD) of experimental duplicates. One representative experiment out of three is shown. E Graphs show the mean (SD)
of the proliferation represented as cell index at 160 h divided by the corresponding cell index at 10 h of three individual experiments. *=P < 0.05;
***=P < 0.001. F Silencing of GARP in osteosarcoma cell lines induce cell death by apoptosis. Apoptosis was measured in NT, LV-CTRL, GARPKO1, and
GARPKO2 G292 (left graph), T1–73 (middle graph), and SAOS-2 (right graph) cells by staining the cells with 7AAD/Annexin V and analysing the cells by
flow cytometry. Data are shown as mean (SD) of three independent experiments. *=P < 0.05.
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injected NT, GARP++, LV-CTRL, and GARPKO2 G292
cells subcutaneously into NSG mice and followed tumour
growth over time. GARP++ G292 tumours exhibited a
significantly increased growth in vivo compared to NT
G292 tumours, whereas smaller tumours were found in
only three out of eight mice injected with GARPKO2 G292
cells (Fig. 3A–C). Furthermore, both volume and weight
of GARP++ tumours isolated from the sacrificed mice
were significantly increased compared to NT tumours
(Fig. 3B), whereas GARPKO2 tumours were significantly
smaller compared to LV-CTRL tumours (Fig. 3C).
GARP++ tumours contained significantly higher levels of
proliferating Ki67+ cells compared to NT tumours while
an opposite trend was observed between GARPKO2 and
LV-CTRL tumours. Finally, we analysed the activation of
SMAD3 in the GARP++ and NT tumours by IHC and
observed an increased fraction of cells with high SMAD3-
phosphorylation in GARP++ tumours compared to NT
tumours (Fig. 3F).
GARP-overexpressing bone sarcoma cell lines are more
resistant to etoposide- and doxorubicin-induced cell
death: dependence on TGF-β
Previous studies on GARP in the context of cancer have
focused on the inhibition of the immune response through
increased activation of TGF-β, especially the induction of
Foxp3+ Tregs19–21. However, to our knowledge, no study
has analysed the effect of GARP expression on the resis-
tance to chemotherapy or radiation. To this end, we added
different concentrations of the DNA damaging agent eto-
poside to NT, EGFP++, GARP++ G292, SAOS-2, and RD-
ES cells and analysed cell survival and apoptosis. We found
Fig. 2 GARP promotes the proliferation of bone sarcoma cell lines through the activation of TGF-β. A Overexpression of GARP in bone
sarcoma cell lines. Representative dot plots of non-transduced (NT) and GARP-overexpressing (GARP++) G292 (top panel), SAOS-2 (middle panel), and
RD-ES (bottom panels). Corresponding isotype staining is represented by vertical lines in all plots. B GARP-overexpression increases the proliferation
of bone sarcoma cell lines. Growth curves of NT, GARP++, and EGFP-overexpressing (EGFP++) G292, SAOS-2, and RD-ES cells were generated by
plotting the cumulative cell numbers vs. time. Data are shown as mean (SD) of three individual experiments. *=P < 0.05. C The fold-increase in cell
numbers of EGFP++ and GARP++ cells in relation to NT cells at the end of each experiment are shown as mean (SD) of three individual experiments.
**=P < 0.01. D GARP++ sarcoma cells produce more active TGF-β compared to NT cells. NT and GARP++ G292, SAOS-2, and RD-ES cells were co-
cultured for 24 h with SBE-HEK293 cells subsequently assayed for luciferase activity. The fold-increase in TGF-β activity of the GARP++ cells is relative
to the NT for each cell line. Data are represented as mean (SD) of three independent experiments. *=P < 0.05, **=P < 0.01. E The increased
proliferation of GARP++ sarcoma cells depends on TGF-β. NT and GARP++ G292, SAOS-2, and RD-ES were cultured in the absence or presence of
SB431542 or anti-TGF-β1/2/3 Ab (11D1) for 3 days and subsequently counted. Fold-increase in cell number is relative to NT for each cell line. Data are
shown as mean (SD) of three independent experiments. *=P < 0.05; **=P < 0.01.
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that GARP-overexpression increased cell survival (Fig. 4A)
and reduced apoptosis (Fig. S4) of all the tumour cell lines.
Inhibition of TGF-β signalling (SB431542) or neutralisation
of TGF-β (1D11) significantly reversed the survival of
GARP-overexpressing cells, suggesting a mechanism
dependent on TGF-β (Fig. 4B). Similarly, GARP++ cells
were more resistant to cell death induced by doxorubicin,
although to a lesser extent compared to etoposide. Again,
inhibition of TGF-β signalling reversed the protective effect
conferred by GARP (Fig. 4C).
GARP-overexpressing sarcoma cells display reduced
sensitivity to radiation-induced cell death and DNA
damage
We next performed a clonogenic assay to assess the
relative resistance of NT and GARP++ sarcoma cells to
radiation-induced cell death. G292 cells did not form
countable colonies, therefore only the SAOS-2 and RD-ES
cell lines were used. The NT and GARP++ cell lines were
subjected to different single doses of radiation (2, 4, and
8 Gy), in the presence or absence of SB431542. Colony
counting showed that GARP++ cells were more resistant
to radiation-induced cell death compared to NT cells.
Inhibition of TGF-β signalling abrogated the GARP-
mediated radioresistance in both cell lines (Fig. 5A, B).
TGF-β has been shown to protect cells against
radiation-induced DNA damage through its effect on
DNA repair31,32. We thus exposed NT and GARP++
SAOS-2 and RD-ES cells, cultured with or without
SB431542 for 24 h, with a single dose of radiation (4 Gy).
We then analysed the induction of DNA damage, as
visualised by the phosphorylation of the H2A histone
family member X (γ-H2AX), before and 2 hours after
radiation using a conventional flow cytometer (Fig. 5C, D)
or an Imagestream flow cytometer in order to visualise the
nuclear foci of γ-H2AX (Fig. 5E, F). We found that
GARP++ cells were more resistant to radiation-induced
DNA damage in a TGF-β-dependent manner (Fig. 5C–F).
Fig. 3 GARP increases the growth of G292 tumours in vivo. A NT (N= 10), LV-CTRL (N= 6), GARPKO2 (N= 10), and GARP++ (N= 10) G292 cells
were injected subcutaneously into NSG mice and tumour growth was followed during 70 days. The tumour height and width were measured weekly
using an automatic calliper and tumour volumes were calculated as described in materials and methods. Data are shown as mean (SD). *=P < 0.05
GARP++ vs. NT. B Representative image of isolated NT and GARP++ tumours at the end of the experiment (top panel). The volumes (left graph) and
weights (right graph) of the isolated tumours were measured as described in materials and methods. Data are shown as mean (SD) with white (NT)
and orange (GARP++) circles representing individual tumours. C Representative image of isolated LV-CTRL and GARPKO2 tumours at the end of the
experiment (top panel). The volumes (left graph) and weights (right graph) of the isolated tumours were measured as described in materials and
methods. Data are shown as mean (SD) with black (LV-GARP) and blue (GARPKO2) circles representing individual tumours. D The proliferation of
tumour cells were analysed by an IHC staining of Ki67 in NT (N= 10) and GARP++ (N= 10) tumours. Data are shown as mean (SD) with white (NT)
and orange (GARP++) circles representing individual tumours. *=P < 0.05. E Staining of Ki67 in LV-CTRL (N= 6) and GARPKO2 (N= 3) tumours. Data
are shown as mean (SD) with black (LV-CTRL) and blue (GARPKO2) circles representing individual tumours. F Activation of the TGF-β signalling
pathway was analysed by phospho-SMAD3 IHC in NT and GARP++ G292 tumours. Data are shown as mean (SD) with open (NT) and orange
(GARP++) circles representing individual tumours. *=P < 0.05. Scale bars: 250 μm (black) or 100 μm (red).
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GARP is highly expressed in human osteo-, chondro-, and
pleiomorphic sarcomas and is associated with a poor
prognosis
The clinical relevance of GARP expression in sarcomas is
unknown. Therefore, we studied the expression of GARP in
primary human bone sarcomas and its correlation with
available clinical data. We first analysed GARP expression
on the cell surface on primary patient-derived cell lines
from two osteosarcomas (OST-3, OST-4) and one chon-
drosarcoma (T-CDS17)28 by flow cytometry. All three cell
lines expressed GARP, albeit at varying levels (Fig. 6A). The
OST-4 cell line expressed GARP at a high level and silen-
cing of GARP reduced its proliferation (Figs. 6B and S5A).
We next analysed the expression of GARP by immuno-
histochemistry (IHC) in a collection of human TMAs,
including samples from 89 patients of 10 types of sarcomas.
GARP was highly expressed in 48% (43/89) of the sarcoma
samples, including all osteosarcoma and undifferentiated
pleomorphic sarcoma cases (Fig. 7A, B). While 73% (8/11)
of chondrosarcomas were positive for GARP, the majority
of synovial sarcomas (7/9) and Ewing Sarcomas (5/6)
expressed low GARP levels (Fig. 7A, B). None of clin-
icopathological variables analysed showed a significant
correlation with the level of GARP expression (Table S1),
although a tendency was observed for a higher grade
(P= 0.15) and mitotic count scoring (P= 0.068) in tumours
showing high expression of GARP (Fig. 7B). Interestingly,
patient cases expressing low GARP levels had a significantly
longer survival time than those with high GARP expression
(94 months (CI 87–100) vs. 41 months (CI 28–54),
respectively; HR 19; P= 0.0001). The 5-year survival rate
was 95.5% for low expressing cases and 35.3% for high
expressing cases (Fig. 7C). Tumour grade, tumour type,
mitotic count, necrosis, and GARP expression level were
included in the multivariate survival analysis. Tumour
necrosis showed an independent prognostic value
(P= 0.024, HR 2.643). Importantly, a tendency was
observed towards high GARP expression having an inde-
pendent prognostic value (P= 0.056) (Table S2). Finally, in
a series of 11 sarcoma patients for which we have response
data to different first-line CT treatments, we found that the
only complete responses occurred in two of the four
patients with low levels of GARP. On the other hand, the
only case where the treatment had no effect on tumour
growth corresponded to a patient with high levels of GARP.
Despite the small number of patients included in this
Fig. 4 GARP-overexpressing bone sarcoma cell lines are more resistant to etoposide- and doxorubicin-induced cell death. Non-transduced
(NT), GARP-overexpressing (GARP++), EGFP-overexpressing (EGFP++) G292, SAOS-2, and RD-ES were subjected to different concentrations of
etoposide in vitro. A Cell viability was measure using CelltiterBlue and plotted as % of control (cells without etoposide). Data are shown as mean (SD)
of three individual experiments. *=P < 0.05; **=P < 0.01; ***=P < 0.001. B NT and GARP++ G292, SAOS-2, and RD-ES cells were subjected to 80 µM
(G292) or 10 µM (SAOS-2 and RD-ES) etoposide, with or without SB431542 and anti-TGF-β1/2/3 Ab (11D1). Cell viability was analysed using
CelltiterBlue and plotted as % of control (cells without etoposide). Data are shown as mean (SD) of three individual experiments. *=P < 0.05. C NT
and GARP++ G292, SAOS-2, and RD-ES cells were subjected to 2.5 µM doxorubicin, with or without SB431542. Cell viability was analysed using
CelltiterBlue and plotted as % of control (cells without doxorubicin). Data are shown as mean (SD) of three independent experiments. *=P < 0.05.
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analysis, we found significant differences between patients
with high and low levels of GARP when performing a
dichotomous analysis of complete responses versus the
other response options (partial response, stable disease, and
progressive disease) (Tables S3 and S4).
Discussion
GARP is emerging as a compelling target in cancer,
both for its role in the function of Tregs which can sup-
press anti-tumour immune responses33, and for its
expression in various cancers19–21. Metelli et al. showed
that overexpression of GARP in the 4T1 murine mam-
mary carcinoma cell line increased its TGF-β activation,
tumour growth, metastasis, and immunoevasive proper-
ties20. Similarly, Hahn et al. showed that GARP is
expressed on human melanoma cells, playing an impor-
tant role in establishing an immunosuppressive tumour
microenvironment19. We and others have previously
shown that GARP is expressed on human MSCs, with
implications for their proliferation, differentiation, and
Fig. 5 GARP-overexpressing bone sarcoma cell lines are more resistant to radiation-induced cell death and DNA damage. The susceptibility
to irradiation was analysed using a clonogenic assay. NT and GARP++ SAOS-2 (A) and RD-ES cells (B) were seeded at low density in 6-well plates and
cultured with or without SB431542 as described in materials and methods. The cells were irradiated with 2, 4, and 8 Gy. After 2 weeks, colonies were
fixed, stained with crystal violet and counted as described in materials and methods. Data are plotted as survival fraction (relative to non-irradiated
cells) and shown as mean (SD) of three independent experiments. *=P < 0.05; ***=P < 0.001 GARP++ vs. NT, #=P < 0.05; ##=P < 0.01; ###=P <
0.001 GARP+++ SB431542 vs. GARP++. NT and GARP++ SAOS-2 (C) and RD-ES (D) cells were cultured with or without SB431542 and irradiated with
4 Gy and analysed for γ-H2AX by flow cytometry. Data are shown as mean (SD) of three independent experiments. NT and GARP++ SAOS-2 (E) and
RD-ES (F) cells were cultured with or without SB431542 and irradiated with 4 Gy and analysed for γ-H2AX using an imagestream flow cytometer. The
number of γ-H2AX foci/nucleus is shown as mean (SD). One representative experiment out of two is shown.
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immunomodulation26,34. However, whether GARP is
expressed by mesenchymal neoplasms and its effect on
chemo/radiation-induced cell death are unknown.
First, we found that GARP is expressed on several bone
sarcoma cell lines, including primary cell lines from osteo-
and chondrosarcoma patients. Silencing of GARP in these
cell lines decreased their proliferation, suggesting that
GARP could serve as a therapeutic target to inhibit bone
sarcoma growth. This is in agreement with Zhou et al.
who demonstrated that GARPlowHeLa cells exhibited
a decreased proliferative rate and an accumulation of
cell cycle-inhibiting proteins, including TP53, cyclin-
dependent kinase inhibitor (CDKN)1 A, and CDKN1B
compared to GARPintermediate cells and GARPhigh cells35.
Although beyond the scope of the current study, under-
standing how GARP regulates the proliferation and sur-
vival of sarcoma cells warrants further investigation.
Second, we show that GARP promotes the capacity of
sarcoma cells to activate TGF-β which suggests that G292,
SAOS-2, and RD-ES cells express the molecules necessary
for GARP-mediated activation of TGF-β36. Furthermore,
we demonstrate that GARP-overexpressing cells exhibit
an increased proliferative capacity, which depended on
TGF-β. Interestingly, blocking TGF-β signalling in NT
sarcoma cells did not affect their proliferation, despite
their basal production of active TGF-β. This could be due
to shortcomings of the experimental setup and to the fact
that GARP-mediated activation of TGF-β occurs in a cell-
contact-dependent manner, inducing a response that
differs from that of TGF-β activated in the absence of
GARP13,36.
Third, we found that high GARP expression on human
sarcoma tumours correlated with a significantly worse
overall survival. Although none of the clinicopathological
variables analysed in this study showed a significant cor-
relation with the level of GARP expression (Table S1), a
tendency was nevertheless observed for a higher grade
(P= 0.15) and mitotic count scoring (P= 0.068). These
data are in agreement with the pro-proliferative properties
of GARP seen in our in vitro and in vivo experiments.
Importantly, a tendency was observed towards GARP
expression having an independent prognostic value (P=
0.056). However, to establish GARP as a prognostic factor
for sarcomas, further correlations between GARP
expression and outcome need to be performed on addi-
tional sarcoma samples.
The current treatment of bone sarcoma is surgery and
multimodal CT, and in some cases RT. In general, dox-
orubicin, cisplatin, and iphosphamide represent first-line
drugs for the treatment of localised bone sarcoma while
Fig. 6 Patient-derived cell lines from osteosarcoma and chondrosarcoma tumours express GARP. A Patient-derived tumour cells were derived
from two osteosarcoma tumours (OST-3 and OST-4) and one chondrosarcoma tumour (T-CDS17). Cell lines were stained for surface expression of
GARP and analysed by flow cytometry. Representative staining are shown. B The proliferation of NT, LV-CTRL, and GARPKO2 OST-4 cells analysed using
xCELLigence real-time cell analyser system. Data are shown as mean (SD) of experimental duplicates. One representative experiment out of two
is shown.
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cyclophosphamide in combination with etoposide are
important for the treatment of recurrent osteosarcoma
and Ewing sarcoma37. As for most solid tumours, the
combination of improved surgical procedures with effi-
cient CT and high-precision RT has substantially
increased the survival rate of bone sarcoma patients.
However, during the last 30 years little progress has been
achieved and patients with metastatic or recurrent dis-
eases still have a <20% chance of long-term survival
despite aggressive therapies37. We show that GARP-
overexpressing SAOS-2 and RD-ES cells, via TGF-β
activation, are more resistant to DNA damage and cell
Fig. 7 Immunohistochemical analysis of GARP expression in sarcoma tissue specimens and impact on patient survival. A Representative
examples of the indicated types of sarcoma showing high and low GARP staining. Scale bars: 250 μm (red) or 50 μm (black). B Distribution of sarcoma
cases (N= 89) according to their GARP expression level across categories of the indicated patient characteristics and tumour clinicopathological
parameters (a more comprehensive description is presented in Supplementary Tables S1 and S2). P values are shown. C Kaplan-Meier cumulative
survival curves categorised by GARP protein expression in the cohort of sarcoma patients. P-values were estimated using the log-rank test.
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death induced by irradiation and etoposide/doxorubicin
in vitro. In addition, in a small group of sarcoma patients
we observed a correlation between GARP expression
levels and the response to CT. However, due to the small
sample size, variety of sarcoma subtypes, and CT mod-
alities, future studies need to analyse the clinical response
of GARPhigh and GARPlow sarcomas to CT and RT, using
larger and more homogenous patient cohorts.
Due to the crucial involvement of TGF-β in cancer
progression and metastasis, there is a great interest in
developing enhanced anti-cancer therapies based on the
inhibition of TGF-β production or signalling (reviewed
in38). However, current anti-TGF-β antagonists do not
distinguish between homeostatic and disease-induced
TGF-β activity and carry the risk of inducing inflamma-
tion, autoimmunity, or cardiovascular defects. Several
clinical trials have employed TGF-β inhibitors for the
treatment of cancer, with positive results achieved for
trabedersen and galunisertib39. However, other trials have
yielded negative results and the risk of adverse effects
remains40–42. Although GARP is not ubiquitous as TGF-
β, its expression is not exclusive to tumour cells. Thus, the
sensitivity of sarcoma cells to GARP inhibition relative to
healthy tissue needs to be addressed. In conclusion, we
propose that GARP might serve as a prognostic and
predictive marker in sarcoma management. We propose
that targeting GARP in sarcomas has the potential of
decreasing tumour burden and increasing the efficacy of
CT and RT. Whether our data on GARP-mediated CT/
RT resistance can be extrapolated to other GARP-
expressing cancers, including colorectal and lung cancer
would be interesting to analyse.
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